Advertisement

Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis

  • Giulio Marchesini
  • Patrizio Pasqualetti
  • Roberto Anichini
  • Salvatore Caputo
  • Giuseppe Memoli
  • Paola Ponzani
  • Veronica Resi
  • Manfredi Rizzo
  • Gaetano Serviddio
  • Giorgio Zanette
Original Article
  • 27 Downloads

Abstract

Aims

Several drug classes are now available to achieve a satisfactory metabolic control in patients with type 2 diabetes (T2DM), but patients’ preferences may differ.

Methods

In a discrete-choice experiment, we tested T2DM patients’ preferences for recent antidiabetic drugs, in the event that their treatment might require intensification. The following attributes were considered: (a) route of administration; (b) type of delivery; (c) timing; (d) risk of adverse events; (e) effects on body weight. Twenty-two possible scenarios were built, transferred into 192 paired choices and proposed to 491 cases naïve to injectable treatments and 171 treated by GLP-1 receptor agonists (GLP-1RAs). Analyses were performed by descriptive statistics and random effects logit regression model.

Results

Preferences according to dosing frequency, risk of nausea and urinary tract infections (UTls) were similar across groups, age, sex and BMI. Administration route and delivery type accounted for 1/3 of relative importance; the risk of UTIs, nausea and dosing frequency for ≈ 20% each, and weight loss for only 6%. Two significant interactions emerged (p < 0.01): type of delivery × group, and weight change × BMI class. Irrespective of previous treatment, the three preferred choices were injectable, coupled with weekly dosing and a ready-to-use device (first two choices). In a regression model, being naïve or non-naïve changed the ranking of preferences (p < 0.001), and the order was systematically shifted towards injectable medications in non-naïve subjects.

Conclusion

Easy-to-deliver, injectable treatment is preferred in T2DM, independently of treatment history, and previous experience with GLP-1RAs strengthens patients’ willingness to accept injectable drugs.

Keywords

Adverse events Dose frequency Glucagon-like peptide-1 receptor agonists Injectable drugs Nausea Oral treatment Route of delivery Sodium–glucose co-transporter 2 inhibitors Urogenital-tract infections Weight loss 

Notes

Acknowledgements

The authors are indebted to Carlo Donato and Andrea Pulazzini, ThinkTank, Milan, Italy, for their support in implementing the DCE methodology.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Research involving human and/or animal rights

All procedures performed in the study were in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

592_2018_1236_MOESM1_ESM.docx (86 kb)
Supplementary material 1 (DOCX 85 KB)

References

  1. 1.
    Bommer C, Heesemann E, Sagalova V et al (2017) The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study. Lancet Diabetes Endocrinol 5:423–430.  https://doi.org/10.1016/S2213-8587(17)30097-9 CrossRefPubMedGoogle Scholar
  2. 2.
    Pagano E, De Rosa M, Rossi E et al (2016) The relative burden of diabetes complications on healthcare costs: the population-based CINECA-SID ARNO Diabetes Observatory. Nutr Metab Cardiovasc Dis 26:944–950.  https://doi.org/10.1016/j.numecd.2016.05.002 CrossRefPubMedGoogle Scholar
  3. 3.
    Zhuo X, Zhang P, Kahn HS et al (2015) Change in medical spending attributable to diabetes: national data from 1987 to 2011. Diabetes Care 38:581–587.  https://doi.org/10.2337/dc14-1687 CrossRefPubMedGoogle Scholar
  4. 4.
    Montilla S, Marchesini G, Sammarco A et al (2014) Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutr Metab Cardiovasc Dis 24:1346–1353.  https://doi.org/10.1016/j.numecd.2014.07.014 CrossRefPubMedGoogle Scholar
  5. 5.
    Farmer AJ, Rodgers LR, Lonergan M et al (2016) Adherence to oral glucose-lowering therapies and associations with 1-year HbA1c: a retrospective cohort analysis in a large primary care database. Diabetes Care 39:258–263.  https://doi.org/10.2337/dc15-1194 CrossRefPubMedGoogle Scholar
  6. 6.
    Krass I, Schieback P, Dhippayom T (2015) Adherence to diabetes medication: a systematic review. Diabet Med 32:725–737.  https://doi.org/10.1111/dme.12651 CrossRefPubMedGoogle Scholar
  7. 7.
    Kennedy-Martin T, Boye KS, Peng X (2017) Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review. Patient Prefer Adherence 11:1103–1117.  https://doi.org/10.2147/PPA.S136639 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Egede LE, Gebregziabher M, Echols C et al (2014) Longitudinal effects of medication nonadherence on glycemic control. Ann Pharmacother 48:562–570.  https://doi.org/10.1177/1060028014526362 CrossRefPubMedGoogle Scholar
  9. 9.
    Encinosa WE, Bernard D, Dor A (2010) Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes. Adv Health Econ Health Serv Res 22:151–173CrossRefPubMedGoogle Scholar
  10. 10.
    Sokol MC, McGuigan KA, Verbrugge RR et al (2005) Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 43:521–530CrossRefPubMedGoogle Scholar
  11. 11.
    Garcia-Perez LE, Alvarez M, Dilla T et al (2013) Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 4:175–194.  https://doi.org/10.1007/s13300-013-0034-y CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    American Diabetes Association (2018) 8. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2018. Diabetes Care 41:S73–S85.  https://doi.org/10.2337/dc18-S008 CrossRefGoogle Scholar
  13. 13.
    Matthaei S, Reaney M, Mathieu C et al (2012) Patients with type 2 diabetes initiating exenatide twice daily or insulin in clinical practice: CHOICE study. Diabetes Ther 3:6.  https://doi.org/10.1007/s13300-012-0006-7 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Reaney M, Mathieu C, Ostenson CG et al (2013) Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study. Health Qual Life Outcomes 11:217.  https://doi.org/10.1186/1477-7525-11-217 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Yu M, Mody R, Lando LF et al (2017) Characteristics associated with the choice of first injectable therapy among US patients with type 2 diabetes. Clin Ther 39:2399–2408.  https://doi.org/10.1016/j.clinthera.2017.11.001 CrossRefPubMedGoogle Scholar
  16. 16.
    Kruger DF, LaRue S, Estepa P (2015) Recognition of and steps to mitigate anxiety and fear of pain in injectable diabetes treatment. Diabetes Metab Syndr Obes 8:49–56.  https://doi.org/10.2147/DMSO.S71923 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Clark MD, Determann D, Petrou S et al (2014) Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics 32:883–902.  https://doi.org/10.1007/s40273-014-0170-x CrossRefPubMedGoogle Scholar
  18. 18.
    Hauber AB, Nguyen H, Posner J et al (2016) A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes. Curr Med Res Opin 32:251–262.  https://doi.org/10.1185/03007995.2015.1117433 CrossRefPubMedGoogle Scholar
  19. 19.
    Gelhorn HL, Poon JL, Davies EW et al (2015) Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naive type 2 diabetes patients in the UK. Patient Prefer Adherence 9:1611–1622.  https://doi.org/10.2147/PPA.S90842 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Purnell TS, Joy S, Little E et al (2014) Patient preferences for noninsulin diabetes medications: a systematic review. Diabetes Care 37:2055–2062.  https://doi.org/10.2337/dc13-2527 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Palmer SC, Mavridis D, Nicolucci A et al (2016) Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316:313–324.  https://doi.org/10.1001/jama.2016.9400 CrossRefPubMedGoogle Scholar
  22. 22.
    Marshall D, Bridges JF, Hauber B et al (2010) Conjoint analysis applications in health—How are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008. Patient 3:249–256.  https://doi.org/10.2165/11539650-000000000-00000 CrossRefPubMedGoogle Scholar
  23. 23.
    Qin L, Chen S, Flood E et al (2017) Glucagon-like peptide-1 receptor agonist treatment attributes important to injection-experienced patients with type 2 diabetes mellitus: a preference study in Germany and the United Kingdom. Diabetes Ther 8:335–353.  https://doi.org/10.1007/s13300-017-0237-8 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Qin L, Chen S, Flood E et al (2017) Glucagon-like peptide-1 receptor agonist treatment attributes important to injection-naive patients with type 2 diabetes mellitus: a multinational preference study. Diabetes Ther 8:321–334.  https://doi.org/10.1007/s13300-017-0230-2 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Matza LS, Boye KS, Currie BM et al (2018) Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes. Curr Med Res Opin.  https://doi.org/10.1080/03007995.2018.1465903:1-8. doi: 10.1080/03007995.2018.1465903CrossRefPubMedGoogle Scholar
  26. 26.
    Matza LS, Boye KS, Stewart KD et al (2017) Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. BMC Health Serv Res 17:774.  https://doi.org/10.1186/s12913-017-2648-7 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Mansfield C, Sikirica MV, Pugh A et al (2017) Patient preferences for attributes of type 2 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther 8:1365–1378.  https://doi.org/10.1007/s13300-017-0326-8 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    American Diabetes Association (2018) 6. Glycemic targets: standards of medical care in diabetes-2018. Diabetes Care 41:S55–S64.  https://doi.org/10.2337/dc18-S006 CrossRefGoogle Scholar
  29. 29.
    Ryden A, Chen S, Flood E et al (2017) Discrete choice experiment attribute selection using a multinational interview study: treatment features important to patients with type 2 diabetes mellitus. Patient 10:475–487.  https://doi.org/10.1007/s40271-017-0225-0 CrossRefPubMedGoogle Scholar
  30. 30.
    Zheng SL, Roddick AJ, Aghar-Jaffar R et al (2018) Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 319:1580–1591.  https://doi.org/10.1001/jama.2018.3024 CrossRefPubMedGoogle Scholar
  31. 31.
    Janssen EM, Hauber AB, Bridges JFP (2018) Conducting a discrete-choice experiment study following recommendations for good research practices: an application for eliciting patient preferences for diabetes treatments. Value Health 21:59–68.  https://doi.org/10.1016/j.jval.2017.07.001 CrossRefPubMedGoogle Scholar
  32. 32.
    Marano G, Cuzzolaro M, Vetrone G et al (2007) Further validation study of the Body Uneasiness Test (BUT) in a clinical sample of 1922 adult obese subjects. Eat Weight Disord 12:70–82CrossRefPubMedGoogle Scholar
  33. 33.
    Flood EM, Bell KF, de la Cruz MC et al (2017) Patient preferences for diabetes treatment attributes and drug classes. Curr Med Res Opin 33:261–268.  https://doi.org/10.1080/03007995.2016.1253553 CrossRefPubMedGoogle Scholar
  34. 34.
    Hauber AB, Tunceli K, Yang JC et al (2015) A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus. Diabetes Ther 6:75–84.  https://doi.org/10.1007/s13300-015-0094-2 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Muhlbacher A, Bethge S (2016) What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences. Eur J Health Econ 17:1125–1140.  https://doi.org/10.1007/s10198-015-0750-5 CrossRefPubMedGoogle Scholar
  36. 36.
    Marchesini G, Forlani G, Rossi E et al (2011) The direct economic cost of pharmacologically-treated diabetes in Italy-2006. The ARNO observatory. Nutr Metab Cardiovasc Dis 21:339–346.  https://doi.org/10.1016/j.numecd.2009.10.009 CrossRefPubMedGoogle Scholar
  37. 37.
    Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296–1310CrossRefGoogle Scholar
  38. 38.
    Abraham NS, Naik AD, Street RL Jr et al (2015) Complex antithrombotic therapy: determinants of patient preference and impact on medication adherence. Patient Prefer Adherence 9:1657–1668.  https://doi.org/10.2147/PPA.S91553 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Joy SM, Little E, Maruthur NM et al (2013) Patient preferences for the treatment of type 2 diabetes: a scoping review. Pharmacoeconomics 31:877–892.  https://doi.org/10.1007/s40273-013-0089-7 CrossRefPubMedGoogle Scholar
  40. 40.
    Rhee MK, Slocum W, Ziemer DC et al (2005) Patient adherence improves glycemic control. Diabetes Educ 31:240–250.  https://doi.org/10.1177/0145721705274927 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  • Giulio Marchesini
    • 1
    • 11
  • Patrizio Pasqualetti
    • 2
  • Roberto Anichini
    • 3
  • Salvatore Caputo
    • 4
  • Giuseppe Memoli
    • 5
  • Paola Ponzani
    • 6
  • Veronica Resi
    • 7
  • Manfredi Rizzo
    • 8
  • Gaetano Serviddio
    • 9
  • Giorgio Zanette
    • 10
  1. 1.SSD Malattie del Metabolismo e Dietetica ClinicaUniversità “Alma Mater”BolognaItaly
  2. 2.Fondazione Fatebenefratelli per la Ricerca e la Formazione Sanitaria e SocialeRomeItaly
  3. 3.Sezione Autonoma di Diabetologia e Malattie MetabolichePresidio Ospedaliero di PistoiaPistoiaItaly
  4. 4.Servizio di Diabetologia, Policlinico GemelliUniversità CattolicaRomeItaly
  5. 5.Centro di Diabetologia “San Luca”Ariano Irpino (AV)Italy
  6. 6.UO di Diabetologia, Ospedale La CollettaArenzano (GE)Italy
  7. 7.Servizio di Diabetologia, UO Endocrinologia e Malattie MetabolicheFondazione IRCCS Ca’ Granda-Ospedale Maggiore, PoliclinicoMilanItaly
  8. 8.Dipartimento Biomedico di Medicina Interna e SpecialisticaUniversity of PalermoPalermoItaly
  9. 9.Dipartimento di Scienze Mediche e ChirurgicheCentro Universitario per la Ricerca e la Cura delle Epatopatie (CURE)FoggiaItaly
  10. 10.SSD di DiabetologiaAzienda OspedalieraPordenoneItaly
  11. 11.Department of Medical & Surgical Sciences“Alma Mater” University, S. Orsola-Malpighi HospitalBolognaItaly

Personalised recommendations